Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?

Author： Morren John A Galvez-Jimenez Nestor

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.11, Iss.18, 2010-12, pp. : 3085-3093

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine

By Silberstein Stephen

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 13, 2012-09 ,pp. : 1961-1968

Informa Healthcare

Access to resources Recommend Favorite

Dihydroergotamine: role in the treatment of migraine

By Schürks Markus

Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, Iss. 9, 2009-09 ,pp. : 1141-1148

Informa Healthcare

Access to resources Recommend Favorite

MT 300: Dihydroergotamine Mesylate Injection - POZEN

Drugs in R&D, Vol. 4, Iss. 2, 2003-01 ,pp. : 133-134

Adis International

Access to resources Recommend Favorite

MT 300 POZEN: Dihydroergotamine Mesylate Injection

By Limited A.I.

Drugs in R&D, Vol. 4, Iss. 6, 2003-01 ,pp. : 376-377

Adis International

Access to resources Recommend Favorite

Complexation of dihydroergotamine mesylate with cyclodextrin derivatives: Solubility and stability in aqueous solution

By Helm H. Muller B.W. Waaler T.

European Journal of Pharmaceutical Sciences, Vol. 3, Iss. 4, 1995-08 ,pp. : 195-201

Elsevier

Access to resources Recommend Favorite